Gut Healing

What "gut healing" actually means in the research

"Gut healing" is a phrase that arrives from a search engine and a comment thread. It is not a phrase that appears in the studies underneath these compounds, and translating between the two is the most useful thing this page can do.

The literature does not study gut healing. It studies a rat colon burned with intrarectal cysteamine and then surgically joined end to end.^[5] It studies a mouse given a chemical irritant in its drinking water until its colon becomes inflamed.^[2] It studies a rat whose small bowel has been resected from the fourth ileal artery to five centimetres below the pylorus, and then watched for four weeks.^[4] It studies how many hours pass before a person who has just had part of their bowel removed can keep down a standardized solid meal.^[6]

Four models, four different questions, and none of them is the question most readers actually have: whether bloating will settle, whether a food will stop causing trouble, whether an inflamed bowel will calm down without escalating medication.

The phrase that fills that gap in popular writing is "leaky gut", and it has a serious literature behind it that is worth reading before deciding what to do. The intestinal barrier is not one thing: it is surface mucus, an epithelial layer, and immune defences, and permeability across it can rise through paracellular transport, apoptosis, or transcellular routes. Permeability really does increase in inflammatory and ulcerating intestinal disease, and it also rises in non-inflammatory "stressed states": endurance exercise, anti-inflammatory drug use, pregnancy, and some dietary emulsifiers. The conclusion clinicians are pointed to is the part that rarely travels with the phrase: no intestinal disease is cured by simply normalising barrier function, and it remains unproven that restoring barrier function improves the clinical manifestations of gastrointestinal or systemic disease.^[9] The barrier is a target for future therapy. It is not yet an established one.

What the evidence supports

Chemically induced colitis and surgical bowel injury, in rats. This is the strongest signal on the page and it belongs entirely to BPC-157. In rats given intrarectal cysteamine together with a colon-to-colon anastomosis, control animals healed neither injury; animals given the peptide intraperitoneally or in drinking water healed both, across doses separated by three orders of magnitude.^[5] The same group reports healing of a surgically created rat colovesical fistula, with resolution of leakage and of stool passing through the fistula, where controls showed persistent defects and advanced adhesion formation.^[7] In a four-week rat short-bowel model, treated animals gained weight from the start instead of losing it progressively, with greater villus height, crypt depth, and anastomosis breaking strength than controls.^[4]

Colitis in mice, through a specific transporter. KPV is the C-terminal three-residue fragment of α-melanocyte-stimulating hormone, pursued as a therapeutic candidate because it retains the parent hormone's anti-inflammatory activity without its pigmentary effect.^[3] Nanomolar concentrations inhibited NF-κB and MAP kinase inflammatory signalling in cultured human intestinal epithelial cells and T cells and reduced pro-inflammatory cytokine secretion; uptake experiments showed the peptide enters those cells through PepT1, a di/tripeptide transporter that is normally a small-intestinal protein and becomes induced in the colon during inflammatory bowel disease. Given orally in drinking water, it reduced the severity of two different chemically induced mouse colitis models.^[2] A later study in a colitis-associated cancer model found that KPV prevented tumour development in wild-type mice and produced none of that effect in PepT1-knockout mice. That is a negative control which strengthens the mechanistic claim without saying anything about people.^[8]

One randomized human trial, and what it measured. Ipamorelin is a ghrelin receptor agonist, and ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract. It was tested for that reason in a multicentre, double-blind, placebo-controlled proof-of-concept trial in adults undergoing small and large bowel resection, with time from first dose to tolerating a standardized solid meal as the key endpoint.^[6] The result is in the next section, because it is not a supporting one.

Where the evidence is weak

One randomized human gastrointestinal trial exists, and it was negative. Median time to a first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference that did not reach significance, and the authors report no significant differences on the key or secondary efficacy analyses.^[6] A negative trial is information. It is also the most rigorous human gut evidence anything on this page has produced.

Almost the entire BPC-157 gastrointestinal literature comes from one research group. The colitis, fistula, and short-bowel studies above share a single laboratory and largely a single set of authors.^[5][7] Reproducibility across independent groups is a normal expectation for a preclinical claim of this size, and it has not happened here.

The "trials for inflammatory bowel disease" claim does not say what it appears to say. The phrase traces to a parenthetical the same group attaches to its own papers, describing a sponsor's earlier programme as safe in inflammatory bowel disease.^[1] No efficacy result from that programme appears anywhere in the published literature, and independent review states the regulatory consequence directly: the compound has not been approved by the FDA or other regulators because sufficient and comprehensive clinical studies confirming benefit in humans are absent.^[10] Reading a safety descriptor as a demonstration of efficacy is the single most common error made about this compound.

KPV's evidence never left the preclinical stage, and the mechanism cuts both ways. The activity that makes the tripeptide interesting depends on a transporter whose expression changes with disease state, demonstrated in mice and in cell lines.^[8] Nothing establishes that the same route operates usefully in a human bowel, and no human trial has tested it.

Three weak evidence bases do not add up to one strong one. Mapping several compounds to a single goal creates an impression of convergence the underlying studies do not support: they converge on plausible mechanisms, not on a shared human outcome. A review covering the unapproved-peptide category treats placebo response, amplified by social media, as a genuine mediator of apparent efficacy. Gut symptoms are among the most placebo-responsive endpoints in medicine.^[11]

The underlying premise is itself unproven. Even granting that a compound tightens an intestinal barrier, the step from there to feeling better has not been demonstrated in humans for any agent.^[9]

How to decide between these

The right comparison is almost never between two peptides. It is between a compound with rodent-only evidence and a standard-of-care option with human evidence for the specific condition in question. The first step is having a condition rather than a description.

Three filters do most of the work. First, get a diagnosis, because "leaky gut" names a mechanism rather than a diagnosis; inflammatory bowel disease, coeliac disease, infection, and functional gut disorders have different evidence bases and different treatments.^[9] Second, decide what counts as evidence for you, because applying "published human efficacy data" as a filter removes everything on this page and leaves one negative trial.^[6] Third, if you compete under anti-doping rules, stop at the section below.

The stack assessment on this site is built to structure that conversation with a clinician rather than to answer it, and its output is a starting point for a visit, not a protocol.

Questions to bring to a provider

The productive version of this conversation is not "should I try BPC-157." It is "here are the symptoms, here is what has been ruled out, and what does the evidence actually offer for what I have."

• What is the working diagnosis, and what does the standard-of-care evidence offer for it specifically?
• Given that the colitis and anastomosis work is entirely in rats and from one laboratory, what would have to be true for an unapproved peptide to be worth considering at all?^[5]
• If the argument rests on repairing the intestinal barrier, how should the finding that no intestinal disease is cured by normalising barrier function change the reasoning?^[9]
• Does a personal or family history of gastrointestinal malignancy change the calculus, given that the tripeptide work was done in a colitis-associated cancer model and that angiogenesis is a proposed mechanism for the pentadecapeptide?^[8][10]
• What objective measure would show whether anything actually changed: endoscopy, imaging, faecal calprotectin, a validated symptom score?
• If competing in a tested sport, what does this year's prohibited list say?

Anti-doping status

Read from the World Anti-Doping Agency Prohibited List in force for 2026, not from the research literature:

• BPC-157: section S0, non-approved substances. S0 covers any pharmacological substance that is not addressed by any later section of the list and has no current approval by any governmental regulatory health authority for human therapeutic use, and BPC-157 is named in it as an example. It is prohibited at all times, in and out of competition. Substances in this class are Specified Substances.
• Ipamorelin: section S2.2.4, growth hormone releasing factors, named among growth hormone secretagogues and their mimetics. Prohibited at all times. Substances in the S2 class are non-Specified Substances, which carries different sanctioning consequences from S0.
• KPV: not named anywhere on the list. That is not the same as permitted. S0 is written as a criterion rather than a roster, and it explicitly reaches compounds under pre-clinical or clinical development. A tripeptide with no marketing approval anywhere for human therapeutic use, and no home in any later section, sits inside that criterion whether or not it appears as an example. This is a reading of the definition and not a naming, which is exactly the kind of question a national anti-doping organization exists to answer.

One caution about this section specifically. The status above is read from the published Prohibited List itself rather than from the research literature, because the research literature has carried it wrongly: a 2025 review of BPC-157 states in its own abstract that the compound's 2022 ban was temporary and that it is not currently listed, and that parenthetical is the origin of a claim that still circulates widely.^[10] The review remains a reasonable survey of the preclinical work; it is not a source for anti-doping status, and neither is any other review.^[11] The list is reissued every year and sections renumber, so a competing athlete should confirm the current year's list rather than this page.